Cited by 965Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, Mark J., Ngiow, Shin Foong, Ribas, Antoni, Teng, Michele W. L.·2016·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2015.209

Open this paper in CoChat — free account

Abstract

Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan for many patients with many cancer types in the near future. There are many types of immune processes involving different antitumour and tumour-promoting leucocytes, and tumour cells use many strategies to evade the immune response. The tumour microenvironment can help determine which immune suppressive pathways become activated to restrain antitumour immunity. This includes immune checkpoint receptors on effector T-cells and myeloid cells, and release of inhibitory cytokines and metabolites. Therapeutic approaches that target these pathways, particularly immune-checkpoint receptors, can induce durable antitumour responses in patients with advanced-stage cancers, including melanoma. Nevertheless, many patients do not have a good response to monotherapy approaches and alternative strategies are required to achieve optimal therapeutic benefit. These strategies include eliminating the bulk of tumour cells to provoke tumour-antigen release and antigen-presenting cell (APC) function, using adjuvants to enhance APC function, and using agents that enhance effector-cell activity. In this Review, we discuss the stratification of the tumour microenvironment according to tumour-infiltrating lymphocytes and PD-L1 expression in the tumour, and how this stratification enables the design of optimal combination cancer therapies tailored to target different tumour microenvironments.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2015.209

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 retracted

TIGIT predominantly regulates the immune response via regulatory T cells
Kurtuluş, S., Sakuishi, K., Ngiow, S. F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 558
Self-citation
Retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citation
Retracted
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E. K., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F. A., Czerwinski, D. K., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
Retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E. K., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A. M. S., Pachynski, R. K., Czerwinski, D. K., Coutre, S. E., et al. (2010) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Show all 218 references

Sorted by citations

Items 501–600 of 965

Longitudinal microcomputed tomography-derived biomarkers for lung metastasis detection in a syngeneic mouse model: added value to bioluminescence imaging
Marien, E., Hillen, A., Vanderhoydonc, F., Swinnen, J. V., & Velde, G. V. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.114 · Cited by 23
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 23
“The TME is more than just tumor and immune cells: stromal cells, blood and lymphatic vessels, extracellular matrix, interstitial ﬂuid, and microbiota all contribute to the immunogenicity of a tumor [267, 268].”
Background
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Schmitt, S., Machui, P., Mai, I., Herterich, S., Wunder, S., Cyprys, P., Gerlach, M., Ochtrop, P., Hackenberger, C. P. R., Schumacher, D., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0359 · Cited by 24
“Such activation of the immune system can lead to a long-lasting protective antitumor immunity and opens a highly promising road for combination of ADCs with immuno-oncology agents (52, 53).”
Background
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy
Xu, Z., Liu, S., Li, Y., Wu, Y., Tu, J., Chen, Q., & Sun, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.039 · Cited by 26
Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer
Chen, H., Xia, B., Zheng, T., & Lou, G. (2019) · The International Journal of Biological Markers · doi:10.1177/1724600819888771 · Cited by 21
Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer
Lee, N. K., Choi, J. U., Kim, H. R., Chung, S. W., Ko, Y. G., Cho, Y. S., Park, S. J., Lee, E. J., Kim, S. Y., Kim, I., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121105 · Cited by 23
A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy
Li, X., Wan, Z., Liu, X., Ou, K., & Yang, L. (2022) · Medical Oncology · doi:10.1007/s12032-021-01635-2 · Cited by 24
Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation
Torkian, P., Haghshomar, M., Farsad, K., Wallace, S., Golzarian, J., & Young, S. J. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28800 · Cited by 22
Engineering near-infrared laser-activated gold nanorod vesicles with upper critical solution temperature for photothermal therapy and chemotherapy
Xing, W., Tang, Y., Ji, Y., Cheng, D., Wang, B., Fu, Y. Z., Xu, Y. F., Qian, X. H., & Zhu, W. P. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.02.049 · Cited by 22
Engineering Ternary PdMop Nanoenzyme for Enzyodynamic Effect‐Enhanced Ferroptosis and Sonocatalysis‐Enabled Tumor Immunotherapy
Song, X., Liu, J., Wang, W., Ding, L., Feng, W., Zhang, T., Chen, Y., & Ni, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202312172 · Cited by 22
Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis
Ortiz, J. A., Maroun‐Eid, C., Martín‐Quirós, A., Lozano‐Rodríguez, R., Llanos-González, E., Toledano, V., Gómez‐Campelo, P., Montalbán-Hernández, K. M., Carballo-Cardona, C., Aguirre, L. A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02008 · Cited by 22
“Recently, blockage of PD-L1/PD-1 crosstalk using an antiPD1 antibody has meant a revolutionary treatment for many types of tumors, such as melanoma, lung, and renal cancers (9, 36, 37).”
Background
Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
Zhang, J., Li, Y., Yang, S. Y. C., Zhang, L., & Wang, W. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100245 · Cited by 22
“Therefore, it is in great need to better understand PD1 biology to prolong its therapeutic efficacy and broaden it to other malignancies [30,34].”
Background
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma
Faiena, I., Comı́n-Anduix, B., Berent-Maoz, B., Bot, A. I., Zomorodian, N., Sachdeva, A., SAID, J. W., Cheung-Lau, G. C., Pang, J., Macabali, M. H., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000336 · Cited by 22
Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer
Jin, Y., Jiang, J. F., Mao, W. B., Bai, M., Chen, Q., & Zhu, J. Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216858 · Cited by 24
Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
Grees, M., Sharbi‐Yunger, A., Evangelou, C., Baumann, D., Cafri, G., Tzehoval, E., Eichmüller, S. B., Offringa, R., Utikal, J. S., Eisenbach, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445457 · Cited by 21
“However, such monotherapies are unlikely to overcome complex mechanisms that impede anti-tumor immunity in patients.(8) Therefore new multivalent and combinatorial therapies are tested now in some ongoing clinical trials that include the targeting of several immune cell populations.”
Background
Human cancer evolution in the context of a human immune system in mice
Gammelgaard, O. L., Terp, M. G., Preiss, B., & Ditzel, H. J. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12374 · Cited by 21
“Following the recent breakthrough of immune checkpoint blockade, stratifying cancers based on the presence of PDL1 and/or TILs in the tumor and surrounding tumor microenvironment (TME) have been suggested as useful parameters for evaluating the state of the anticancer immune response and thus the potential for therape…”
Background
Hybrid spherical nucleotide nanoparticles can enhance the synergistic anti-tumor effect of CTLA-4 and PD-1 blockades
Zhang, J., Liu, D., Liu, J., Han, Y., Xu, H., Leng, X., Kong, D., & Liu, L. (2020) · Biomaterials Science · doi:10.1039/d0bm00908c · Cited by 21
The Immune Heterogeneity Between Pulmonary Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Analysis Based on lncRNA Model
Yan, T., Ma, G., Wang, K., Liu, W., Zhong, W., & Du, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.547333 · Cited by 21
Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts
Gao, Z., Wang, L., Song, Z., Ren, M., Yang, Y., Li, J., Shen, K., Li, Y., Ding, Y., Yang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954039 · Cited by 21
“There is growing evidence that the tumor microenvironment (TME) is essential for tumorigenesis, tumor progression and regulation of immune responses (12).”
Background
The effects of ARID1A mutation in gastric cancer and its significance for treatment
Lü, S., Duan, R., Liang, C., & Song, Y. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03154-8 · Cited by 23
“According to other research findings, combining PI3K/AKT/mTOR inhibitors with ICIs (which include PD-1 inhibitors in parallel with CTLA-4 inhibitors) or other anti-tumor immunotherapy may enable patients to obtain the best efficacy [91].”
Method
Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (β-amino ester) nano-vaccines for melanoma
Zou, C., Jiang, G., Gao, X., Zhang, W. J., Deng, H., Zhang, C., Ding, J., Wei, R., Wang, X., Xi, L., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102092 · Cited by 21
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment
Widodo, S. S., Hutchinson, R. A., Fang, Y., Mangiola, S., Neeson, P. J., Darcy, P. K., Barrow, A. D., Hovens, C. M., Dinevska, M., Stylli, S. S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02801-7 · Cited by 20
Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy
Meng, X., Lei, Y., Zhang, X., Sun, K., Zhang, L., & Wang, Z. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101149 · Cited by 23
Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
Thomas, G. D., Micci, L., Yang, W., Katakowski, J. A., Oderup, C., Sundar, P. D., Wang, X., Geles, K. G., Potluri, S., & Salek‐Ardakani, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.711673 · Cited by 20
“As cancer immunotherapy approaches frequently rely upon combinations (6, 28), these findings highlight the importance of appreciating the broader implications of agents’ effects on the tumor immune microenvironment in order to ensure such combinations are both rational and complementary.”
Background
N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma
Cai, J., Zhou, M., & Xu, J. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02354-8 · Cited by 20
“In recent years, emerging immunotherapies, such as immune checkpoint blockade and chimeric antigen receptor t cell (CAR-T) immunotherapy, have shown better therapeutic outcomes for some tumors [6, 7].”
Background
Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia
Zhang, L., Jin, Y., Xia, P., Lin, J., Ma, J., Li, T., Liu, Z., Xiang, H., Chen, C., Xu, Z., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4284 · Cited by 19
Cytotoxicity - Understanding Cellular Damage and Response
Sukumaran, A., & Mansour, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100956 · Cited by 22
The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
Zhang, J., Li, R., & Huang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.951019 · Cited by 19
A DNA-polymer hybrid nanocomplex based bi-adjuvant vaccine for tumor immunotherapy
Li, F., Ding, X., Lv, Z., Li, J., & Yang, D. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102061 · Cited by 20
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
Pinto, G. D. J., Viana, L. D. S., Scapulatempo‐Neto, C., & Serrano, S. V. (2016) · Journal of Immunology Research · doi:10.1155/2016/9839685 · Cited by 20
“argue that a successful cancer treatment must be precisely based on the stratification of tumor microenvironment and besides that it should not be restricted only to immune checkpoints but also to potentially involved cell types [42], as they are best studied and characterized.”
Background
CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells
Abé, H., Saito, R., Ichimura, T., Iwasaki, A., Yamazawa, S., Shinozaki‐Ushiku, A., Morikawa, T., Ushiku, T., Yamashita, H., Seto, Y., et al. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2332-2 · Cited by 21
IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma
Jiao, R., Zheng, X., Sun, Y., Feng, Z., Song, S., & Ge, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01099 · Cited by 20
“Our study also manifested that the density of CD8+TILs increased significantly after NCRT compared with NCT, which might be because the addition of radiotherapy caused tumor cells to release more tumor-associated antigens and damage-associated pattern molecules to induce more numbers of CD8+TILs and immunogenic cell d…”
Result
Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development
Zdrehus, R. S., Delcea, C., & MOCAN, L. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030410 · Cited by 19
“Therapeutic approaches that target these pathways, particularly immune checkpoint receptors, have the potential to induce durable antitumor responses in patients with advanced cancer [68].”
Background
Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells
Zimarino, C., Moody, W., Davidson, S. E., Munir, H., & Shields, J. D. (2024) · iScience · doi:10.1016/j.isci.2024.109546 · Cited by 19
Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases
de Miranda, F. S., Guimarães, J. P. T., Menikdiwela, K. R., Mabry, B., Dhakal, R., Rahman, R. L., Moussa, H. M., & Moustaïd‐Moussa, N. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111245 · Cited by 19
Autologous tumor antigens and boron nanosheet‐based nanovaccines for enhanced photo‐immunotherapy against immune desert tumors
Sun, Z., Fan, T., Liu, Q., Huang, L., Hu, W., Shi, L., Wu, Z., Yang, Q., Liu, L., & Zhang, H. (2021) · Nanophotonics · doi:10.1515/nanoph-2021-0229 · Cited by 18
Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 22
“Dominolike” Barriers Elimination with an Intratumoral Adenosine-Triphosphate-Supersensitive Nanogel to Enhance Cancer Chemoimmunotherapy
Zhang, F., Dong, J., Huang, K., Duan, B., Li, C., Yang, R., Li, J., Zhi, F., Zhou, Z., & Sun, M. (2023) · ACS Nano · doi:10.1021/acsnano.3c03386 · Cited by 19
Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target
Mu, Y., Rogers, L. J., Suchowerska, N., Choe, D. J., Al‐Dabbas, M. A., Narula, R. S., Lyons, J. G., Sved, P. D., Zhong, L., & Dong, Q. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.021 · Cited by 20
Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
Yan, J., Allen, S. M., Vijayan, D., Li, X.-Y., Harjunpää, H., Takeda, K., Liu, J., Cua, D. J., Smyth, M. J., & Teng, M. W. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0011 · Cited by 19
“Tumor-induced immune suppression, used by tumors to evade immune destruction (1), can be mediated through lymphoid and myeloid cells.”
BackgroundSelf-citation
Liquid biopsy for lung cancer immunotherapy (Review)
Cai, L., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10166 · Cited by 19
“According to a useful pragmatic framework reported by Teng et al (54) and Smyth et al (55), TME can be stratified into four types: Type I [tumor‑infiltrating lymphocyte (TIL)+, PD-L1+], Type II (TILs-, PD-L1-), Type III (TIL-, PD-L1+) and Type IV (TIL+, PD-L1-) (Fig.”
Method
Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155
Wang, Y., Luo, Y., Chen, Y., Lu, Z.-D., Wang, Y., Czarna, A., Shen, S., Xu, C., & Wang, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01420f · Cited by 19
Imaging of T-cell Responses in the Context of Cancer Immunotherapy
Xiao, Z., & Puré, E. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0678 · Cited by 19
“Clinical trials have shown that T-cell infiltration status is highly associated with patients’ prognosis (25) and treatment responses to immunotherapy (26).”
Background
Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor–Immune Interactions
Liu, T. W., Gammon, S. T., Fuentes, D., & Piwnica-Worms, D. (2021) · Cells · doi:10.3390/cells10030489 · Cited by 16
Dual Oxygen‐Supply Immunosuppression‐Inhibiting Nanomedicine to Avoid the Intratumoral Recruitment of Myeloid‐Derived Suppressor Cells
Yang, Z., Zuo, H., Hou, Y., Zhou, S., Zhang, Y., Yang, W., He, J., Shen, X., & Peng, Q. (2024) · Small · doi:10.1002/smll.202406860 · Cited by 19
Solid lipid nanoparticles in cervical cancer: a comprehensive review of a decade of progress and prospects
Tiwary, P., Oswal, K., Varghese, R., Peri, R. V., & Gupta, P. K. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00109a · Cited by 19
Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric field
Liu, J., Chen, X., & Zheng, S. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0747-z · Cited by 17
An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma
Liu, Z., Sun, L., Peng, X., Liu, S., Zhu, Z., & Huang, C. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01879-5 · Cited by 18
“The majority of patients with low responsiveness to ICIs are mainly related to “cold tumors”, which lack infiltrating T cells and have an immunosuppressive Tumor microenvironment (TME) [10–12].”
Background
Small EV-based delivery of CpG ODNs for melanoma postsurgical immunotherapy
Lu, Y., Ye, H., Zhao, J., Wang, K., Fan, X., Qi, L., Cao, L., Wan, B., Liu, F., Sun, F., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.065 · Cited by 18
CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer
Zeng, Y. C., Li, B., Li, T., Liu, W., Ran, C., Penson, R. T., Poznansky, M. C., Du, Y., & Chen, H. (2019) · Oncotarget · doi:10.18632/oncotarget.27065 · Cited by 18
“The development of cancer immunotherapies favors combination strategies for enhancing APC function and enhancing T cell effector activity while eliminating immunosuppression [24].”
Background
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
Chen, J., Liu, H., Jehng, T., Li, Y., Chen, Z., Lee, K., Shen, H.-T., Jones, L. E., Huang, X. F., & Chen, S. (2019) · Cancers · doi:10.3390/cancers11121909 · Cited by 18
Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE)
Ahern, E. S., Allen, M. J., Schmidt, A. L., Lwin, Z., & Hughes, B. G. M. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13350 · Cited by 18
“Median number of admissions for all admitted patients (range) 1 (1-5)”
Background
FXIIIa substrate peptide decorated BLZ945 nanoparticles for specifically remodeling tumor immunity
Wei, Q., Shen, N., Yu, H., Wang, Y., Tang, Z., & Chen, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00713g · Cited by 18
PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics
Sidi, F. A., Bingham, V., Craig, S. G., McQuaid, S., James, J. A., Humphries, M. P., & Salto‐Tellez, M. (2020) · Cancers · doi:10.3390/cancers13010029 · Cited by 18
“led to significant breakthroughs in the treatment of malignancies associated with these immune checkpoint proteins [1,2].”
Background
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
Giustozzi, M., Becattini, C., Roila, F., Agnelli, G., & Mandalà, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102280 · Cited by 19
mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy
Braun, C., & Weichhart, T. (2021) · European Journal of Immunology · doi:10.1002/eji.202149270 · Cited by 18
Macrophage regulation of B cell proliferation
Goldman, N., Valiuskyte, K., Londregan, J., Swider, A., Somerville, J. E., & Riggs, J. E. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.02.002 · Cited by 18
“These efforts have informed novel clinical approaches and fostered an exciting era of T cell-focused immunotherapies [5,8].”
Background
Proton-Gradient-Driven Porphyrin-Based Liposome Remote-Loaded with Imiquimod as In Situ Nanoadjuvants for Synergistically Augmented Tumor Photoimmunotherapy
Liu, D., Fu, L., Gong, L., Li, S., Li, K., Liu, K., & Yang, D. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17133 · Cited by 17
An ecosystem framework for understanding and treating disease
Hochberg, M. (2018) · Evolution Medicine and Public Health · doi:10.1093/emph/eoy032 · Cited by 16
“Combination therapies have become a mainstay for treating HIV, malaria and tuberculosis and are particularly relevant to cancers [133, 145, 155].”
Background
Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement
Алексеенко, И. В., Kuzmich, A. I., Kondratyeva, L. G., Kondratieva, S. A., Pleshkan, V. V., & Sverdlov, E. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179376 · Cited by 17
Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma
Zhang, H., Zhang, Y., Dong, J., Zuo, S., Meng, G., Wu, J., & Wei, J. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00633-w · Cited by 18
Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning
Feng, H., Zhao, Y., Yan, W., Wei, X., Lin, J.-P., Jiang, P., Wang, C., & Li, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.843749 · Cited by 17
“Diﬀerent tumor types adopt diﬀerent strategies to escape the immune surveillance and killing of tumor cells by the immune system, thereby generating immune tolerance and promoting tumor occurrence and development (2).”
Background
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 19
Intravital Microscopy for Imaging the Tumor Microenvironment in Live Mice
Naumenko, V., Jenne, C. N., & Mahoney, D. J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3801-8_16 · Cited by 17
Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers
Santana-Dávila, R., Bhatia, S., & Chow, L. Q. M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4574 · Cited by 17
“Serumspecific and tissue-specific viral markers and quantitative viral levels are still being assessed as prognostic and predictive markers in conjunction with the above biomarkers in many immunotherapy investigations.(50) In a rapidly evolving world of immunotherapy for solid tumors, successful targeting of the immun…”
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
Day, D., Monjazeb, A. M., Sharon, E., Ivy, S. P., Rubin, E. H., Rosner, G. L., & Butler, M. O. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3064 · Cited by 17
“For example, the aforementioned stratification of the TME based on PD-L1 status and lymphocytic infiltration has been described to guide treatment options (32, 83).”
Background
Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
Cui, H., Dai, G., & Guan, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s234868 · Cited by 17
“Immune checkpoint inhibitor (ICI) demonstrated encouraging efficacy in certain cancer types, particularly in melanoma and lung cancer.(12) Programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyteassociated protein-4 (CTLA-4) are the main targets of ICIs.”
Background
Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells
Carlo, E. D. (2020) · Cells · doi:10.3390/cells9030615 · Cited by 17
“Immunotherapy, in particular checkpoint inhibitors, has led to an epoch-making progress in the treatment of advanced cancers [96,97].”
Background
Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy
He, L.-N., Fu, S., Zhang, X., Hu, Q., Du, W., Li, H., Chen, T., Chen, C., Jiang, Y., Zhou, Y., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.030 · Cited by 17
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
Souza-Fonseca-Guimarães, F., Blake, S. J., Makkouk, A., Chester, C., Kohrt, H. E. K., & Smyth, M. J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1192740 · Cited by 16
Self-citation
Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers
Wen, P., Gao, Y., Chen, B., Qi, X., Hu, G., Xu, A., Xia, J., Wu, L., Lü, H., & Zhao, G. (2020) · Cancers · doi:10.3390/cancers12040957 · Cited by 16
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma
Tripathi, S., Najem, H., Mahajan, A., Zhang, P., Low, J., Stegh, A. H., Curran, M. A., Ashley, D. M., James, C. D., & Heimberger, A. B. (2022) · F1000Research · doi:10.12688/f1000research.125163.1 · Cited by 16
“A prototypical example involves PD-L1 expression and the presence of tumor-infiltrating lymphocytes.(89) For STING agonists, the presence of myeloid cell/APC infiltration in the tumor is required for anti-tumor T cell response.”
Background
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Bao, L., Zhu, P., Mou, Y., Song, Y., & Ye, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214675 · Cited by 17
“On the other hand, positive factors such as immune supporting cytokines, immunogenic cancer cell death, and professional antigen-presenting cells promote immune clearance (86).”
Background
Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
Qi, X., & Lam, S. S. K. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000438 · Cited by 16
“Immunotherapy represents one of the most promising approaches in the treatment of cancers [7].”
Background
Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model
Kruse, S., Büchler, M., Uhl, P., Sauter, M., Scherer, P., Lan, T. C. T., Zottnick, S., Klevenz, A., Yang, R., Rösl, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524694 · Cited by 16
Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics
Yang, L., Wang, J., Zhang, T., Wang, H., & Li, L. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00865 · Cited by 16
“Some genes that targets co-occurred with, such as BRAF, PDGFRB, APC, IGF1R , and MTOR, have been targeted by drugs to treat tumor progression (Wang et al., 2014; Kavuri et al., 2015; Long et al., 2015; Smyth et al., 2016; David et al., 2017; Zhang et al., 2018; Sullivan et al., 2019).”
Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor
Li, X., Yu, Z., & Li, S. (2021) · Materials & Design · doi:10.1016/j.matdes.2021.109958 · Cited by 16
Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy
Mandalà, M., Tondini, C. A., Merelli, B., & Massi, D. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0282-0 · Cited by 16
Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer
Du, J., Su, S., Li, H., Shao, J., Meng, F., Yang, M., Qian, H., Zou, Z., Qian, X., & Liu, B. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5305 · Cited by 16
“Adoptive cellular immunotherapy (ACI), a developing cancer therapeutic, is able to mobilize and strengthen the body's immune system to kill cancer cells; however, clinical trials using ACI have yielded low objective response rates (1).”
Background
The Impact of T-cell Exhaustion Dynamics on Tumour–Immune Interactions and Tumour Growth
Lai, N., Farman, A., & Byrne, H. M. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01433-1 · Cited by 19
“…have been administered alone and in combination with other treatments, such as radiotherapy and chemotherapy, yielding marked improvements in patient survival rates and quality of life compared with the current standard of care (Esfahani et al. 2020; Hall et al. 2013; Smyth et al. 2016).”
Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors
Yang, X., Cai, S., Liu, X., Chen, P., Zhou, J., & Zhang, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.005 · Cited by 15
Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment
Bazzichetto, C., Conciatori, F., Falcone, I., & Ciuffreda, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35582-1_4 · Cited by 14
An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer
Han, Y. J., Zhang, J., Hardeman, A., Liu, M., Karginova, O. A., Romero, R., Khramtsova, G. F., Zheng, Y., Huo, D., & Olopade, O. I. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac168 · Cited by 15
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy
Mu, Y., & Guan, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230324152532 · Cited by 15
RNA splicing alterations in lung cancer pathogenesis and therapy
Yan, Y., Ren, Y., Bao, Y., & Wang, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.04.004 · Cited by 16
“66 However, only a fraction of patients respond to ICB, calling for a deeper understanding of immune-escape mechanisms.”
Background
Advances in photo-responsive hydrogel integrated with biomedical materials for antitumor applications
Chen, Z., Chen, T., Guo, B., & Yang, F. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113431 · Cited by 15
A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model
Huang, J., Zhang, D., Bai, Y., Yang, P. B., Xing, L., & Yu, J. (2020) · Journal of Cancer · doi:10.7150/jca.43966 · Cited by 15
“However, only a fraction of patients benefit from immunotherapy, due to some factors within the tumor microenvironment (TME) that mitigate immune cell infiltration and suppress antitumor immune responses [1].”
Background
Productive screening of single aptamers with ddPCR
Chen, J., Wang, J., Luo, Z., Fang, X., He, L., Zhu, J., Zahra, Q. U. A., He, J., Ma, H., Zhang, H., et al. (2020) · The Analyst · doi:10.1039/d0an00460j · Cited by 15
Acid-responsive endosomolytic polymeric nanoparticles with amplification of intracellular oxidative stress for prodrug delivery and activation
Lu, N., Xi, L., Zha, Z., Wang, Y., Han, X., & Ge, Z. (2021) · Biomaterials Science · doi:10.1039/d1bm00159k · Cited by 15
A prognostic value of CD45RA+, CD45RO+, CCL20+ and CCR6+ expressing cells as ‘immunoscore’ to predict cervical cancer induced by HPV
Fernandes, A. T. G., Carvalho, M. O. O., Portari, E. A., da Rocha, N. P., Russomano, F. B., Roma, E. H., & Bonecini-Almeida, M. D. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-88248-x · Cited by 15
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000262 · Cited by 16
Polymeric Matrix-Based Nanoplatforms toward Tumor Therapy and Diagnosis
Zhu, H., Loh, X. J., Ye, E., & Li, Z. (2021) · ACS Materials Letters · doi:10.1021/acsmaterialslett.1c00558 · Cited by 15
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
Hsu, M. M., & Balar, A. V. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.009 · Cited by 15
Immune Checkpoint Inhibitors–Related Cardiotoxicity
Konala, V. M., Adapa, S., & Aronow, W. S. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000988 · Cited by 15
Tailoring precision immunotherapy: coming to a clinic soon?
Han, S., Shuen, T. W. H., Wang, W.-W., Nazim, E., & Toh, H. C. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000631 · Cited by 16
Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model
Zhang, Z., Zhou, H., Liu, Y., Ren, J. L., Wang, J., Sang, Q., Lan, Y., Wu, Y., Yuan, H., Ni, W., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108173 · Cited by 15
3,3′-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells
Sun, Q., Xiao, L., Cui, Z., Yang, Y.-P., Ma, J., Huang, Z., Zhang, J.-F., & Chen, J.-N. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00638-z · Cited by 13
Highly Sensitive Detection of the Immune Checkpoint PD-L1-Positive Circulating Tumor Cells Based on Steric Hindrance
Gong, Y., Yao, Y., Cheng, W., Duan, C., Li, D., Wang, Z., & Xiang, Y. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01762 · Cited by 14
Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
Matteucci, L., Bittoni, A., Gallo, G., Ridolfi, L., & Passardi, A. (2023) · Cancers · doi:10.3390/cancers15215189 · Cited by 15
Single-cell RNA sequencing indicates cordycepin remodels the tumor immune microenvironment to enhance TIGIT blockade's anti-tumor effect in colon cancer
Chen, R., Feng, C., Chen, L., Zheng, X. W., Fang, W., Wu, S., Gao, X., Chen, C., Yang, J., Wu, Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111268 · Cited by 14

Authors: Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L.
Affiliations: QIMR Berghofer Medical Research Institute (AU)
University of California, Los Angeles (US)
Corresponding author: Teng, Michele W. L.
ORCID: Smyth, Mark J.
Ngiow, Shin Foong
Ribas, Antoni
Teng, Michele W. L.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2015-11-24
Volume: 13
Issue: 3
Pages: 143-158
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2015.209
OpenAlex: W2257916459
Cited by: 944
References: 218
Citations by year: 2026: 28 · 2025: 50 · 2024: 71 · 2023: 82 · 2022: 132 · 2021: 102 · 2020: 134 · 2019: 95 · 2018: 99 · 2017: 89 · 2016: 56 · 2015: 3
FWCI: 8.83
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
Kite Pharma
National Cancer Institute (R35CA197633)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, combination therapy, tumor microenvironment, immune evasion, immune checkpoint receptors, PD-L1, tumor-infiltrating lymphocytes, myeloid cells, inhibitory cytokines, antigen-presenting cells, adjuvants, melanoma
MeSH terms: Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunotherapy, Neoplasms, Signal Transduction, Treatment Outcome, Tumor Escape, Molecular Targeted Therapy, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combination cancer immunotherapies tailored to the tumour microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks